The global metastatic castration-sensitive prostate cancer treatment market is witnessing significant growth. This boom can be attributed to factors such as an growing older population, rising prevalence of prostate cancer, and developments in treatment choices. The market is moreover driven by enhanced understanding about the disease and its thera